Reply to R.L. Bowen et al, M. Froehner et al, J.L. Leow et al, and C. Brady et al.

Nead, Kevin T; Gaskin, Greg; Chester, Cariad; Swisher-McClure, Samuel; Dudley, Joel T; Leeper, Nicholas J; Shah, Nigam H

Nead, Kevin T; Gaskin, Greg; Chester, Cariad; Swisher-McClure, Samuel; Dudley, Joel T; Leeper, Nicholas J; Shah, Nigam H.

Afiliação

Nead KT; Stanford University, Stanford, CA, and University of Pennsylvania Perelman School of Medicine, Philadelphia, PA kevin.nead@uphs.upenn.edu.
Gaskin G; Stanford University, Stanford, CA.
Chester C; Stanford University School of Medicine, Stanford, CA.
Swisher-McClure S; University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
Dudley JT; Icahn School of Medicine at Mount Sinai, New York, NY.
Leeper NJ; Stanford University School of Medicine, Stanford, CA.
Shah NH; Stanford University, Stanford, CA.

J Clin Oncol ; 34(23): 2804-5, 2016 08 10.

Article em En | MEDLINE | ID: mdl-27298415

Assuntos

Doença de Alzheimer; Antagonistas de Androgênios/efeitos adversos; Humanos; Masculino; Risco

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Alzheimer / Antagonistas de Androgênios Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Humans / Male Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google